💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

MYOS RENS inks deal with University of California to study effects of Fortetropin on skeletal muscle protein synthetic rate

Published 12/06/2017, 07:45 AM
© Reuters.  MYOS RENS inks deal with University of California to study effects of Fortetropin on skeletal muscle protein synthetic rate
MDVLQ
-
  • MYOS RENS Technology (NASDAQ:MYOS) announces that it has entered into a research agreement with the University of California, Berkeley's Department of Nutritional Sciences & Toxicology.
  • The study will look into the effects of Fortetropin on increasing the fractional rate of skeletal muscle protein synthesis in men and women between 60 and 75 years old. It will involve 20 subjects that will take either Fortetropin or placebo for 21 days along with daily doses of a heavy water tracer.
  • After 21 days, a microbiopsy will be collected from each subject to determine the fractional rate of muscle protein synthesis. The clinical study is expected to be completed in the H2 2018.
  • Fortetropin is the all-natural food ingredient clinically shown to increase muscle size, lean body mass and strength as part of resistance training.
  • Now read: Scynexis: This Cash-Rich Biotech Stock Is A Strong Buy Before 2018


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.